Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences
August 27 2014 - 4:05PM
Business Wire
Two Presentations to be Webcast
September 4 at 2:00 P.M. ET and September 8
at 2:00 P.M. ET
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a research and
development-focused biotechnology company dedicated to creating
small molecule drugs in the infectious disease field, today
announced that Jay R. Luly, Ph.D., President and Chief Executive
Officer, and other members of Enanta management will participate in
the following three investor conferences during the month of
September:
- Wednesday, September 3, 2014, the FBR
& Company Inaugural Healthcare Conference in Boston. There is
no webcast presentation.
- Thursday, September 4, 2014, at 2:00
p.m. ET, Enanta management will present a corporate overview during
the Baird 2014 Healthcare Conference in New York.
- Monday, September 8, 2014 at 2:00 p.m.
ET, Enanta management will present a corporate overview during the
Morgan Stanley 2014 Global Healthcare Conference in New York.
Live webcasts and replays of the Baird 2014 Healthcare
conference and the Morgan Stanley 2014 Global Healthcare conference
presentations can be accessed by visiting the “Calendar of Events”
section on the “Investors” page of Enanta’s website at
www.enanta.com. A replay of each webcast will be available
following the presentation and will be archived for approximately
30 days.
About Enanta
Enanta Pharmaceuticals is a research and development-focused
biotechnology company that uses its robust chemistry-driven
approach and drug discovery capabilities to create small molecule
drugs in the infectious disease field. Enanta is discovering, and
in some cases developing, novel inhibitors designed for use against
the hepatitis C virus (HCV). These inhibitors include members of
the direct acting antiviral (DAA) inhibitor classes – protease
(partnered with AbbVie), NS5A (partnered with Novartis) and
nucleotide polymerase – as well as a host-targeted antiviral (HTA)
inhibitor class targeted against cyclophilin. Additionally, Enanta
has created a new class of antibiotics, called Bicyclolides, for
the treatment of multi-drug resistant bacteria, with a focus on
developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus)
infections.
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2023 to Apr 2024